fda halts glp-1 The has issued a warning to Novo Nordisk over its alleged failure to report adverse side effects, including death, in patients who took its medications, popularly known as Ozempic and US signals crackdown on compounded

Sometimes the most sophisticated metabolic tools are not found in a prescription bottle

Stable blood sugar can support stable energy, stable mood, and freedom from the 3 PM crash many women experience that often drives snacking

The FDA continues to explain GLP-1 drugs should not be used in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2). Today, experts agree that there is no real risk of thyroid cancer associated with GLP-1 drugs

Weight Loss and Body Composition Outcomes with OnceWeekly Semaglutide. Journal of Clinical Endocrinology & Metabolism, vol

In an email to Drug Discovery & Development , Nicholas Chimicles, lead counsel for the plaintiffs, declined to comment further on the litigation but said the firm was aware of the recent New York Times profile of MEDVi